Public Citizen criticizes Lunesta pricing

Share this article:
Consumer advocacy group Public Citizen has made Massachusetts pharmaceutical company Sepracor its latest industry target, criticizing the company over pricing of its sleep aid Lunesta.
According to a Bloomberg News report, Sepracor charges nearly $99 for a 30-day supply of Lunesta versus $87.99 for a 30-day supply of Sanofi-Aventis' Ambien, a primary competitor and the global sales leader.
Generic versions of Ambien sell for $12.99 for a 30-day supply, Public Citizen said.
The group also claimed Sepracor gained approval for Lunesta despite a concern about cancer risks, after a senior FDA official overruled the objections and the agency instead sought more information. 
Sepracor told Bloomberg News that Public Citizen's assertions were wrong and that the FDA issued a "universal decision to approve this drug."
Sepracor is hoping Lunesta will achieve positive results, spending $100 million to market the drug and boosting its work force by 900 employees to help sell it.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.